tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Beijing Biostar Pharmaceuticals Updates Inventory Pricing and Financial Reporting Standards

Story Highlights
Beijing Biostar Pharmaceuticals Updates Inventory Pricing and Financial Reporting Standards

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ).

Beijing Biostar Pharmaceuticals Co., Ltd. announced a corrigendum to a previous board resolution, clarifying changes in its inventory pricing method and financial reporting standards. The company will switch from a first-in-first-out to a weighted average method for inventory pricing to better reflect cost fluctuations and improve decision-making. Additionally, it confirmed the use of both China Accounting Standards for Business Enterprises and Hong Kong Financial Reporting Standards for its financial statements.

More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H

Beijing Biostar Pharmaceuticals Co., Ltd. is a pharmaceutical company based in the People’s Republic of China. It operates in the biopharmaceutical industry, focusing on the development and production of innovative medical products.

Average Trading Volume: 1,495,166

Technical Sentiment Signal: Hold

Learn more about 2563 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1